温馨提醒：文章旨在传递疾病知识，不作为诊疗方案推荐及医疗依据。
封面图片来源：稿定+摄图网，未经允许请勿转载
责任编辑：觅健美美
参考文献：
[1] Kuksis M, Gao Y, Tran W, et al. The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis. Neuro Oncol. 2021 Jun 1;23(6):894-904.
[2] PEREZ EA，,et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABPB-31 and NCCTGN9831[J]． J clin oncol 2014, 32(20):3744-3752．
[3] De Azambuja E, et al. Trastuzumab—associ ated cardiac events at 8 years of median follow-up in the HERceptin Adjuvant trial(BIG1-01)[J]. J clin oncol, 2014,32(20):2159-2165．
[4] Romond EH, et al. Seven year follow-up assessment of cardiac functionin NSABPB-31. a randomized trial comparing doxombicin and cyclo-phosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with nodepositive, human epidermal growth factor recept or 2-positive breast cancer[J]. J clin oncol 2012(30):3792-3799．
[5] Camerond D,et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2- positive early breast cancer:final analysis of the Herceptin Adjuvant (HERA) trial [J]. The Lancet,2017,389( 10075):1195．
[6]Chan A, Moy B, Mansi J, et al. Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. Clin Breast Cancer. 2021 Feb;21(1):80-91.e7.
[7]Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Dec;18(12):1688-1700.
[8]Burstein HJ, Curigliano G, Thürlimann B, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021 Oct;32(10):1216-1235.
[9]Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Dec;18(12):1688-1700.
[10]van Mackelenbergh MT, Loibl S, Untch M, et al. Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. J Clin Oncol. 2023 Jun 1;41(16):2998-3008.
[11]Hurvitz SA, Martin M, Jung KH, et al. Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. J Clin Oncol. 2019 Sep 1;37(25):2206-2216.
